Contineum Therapeutics In...

AI Score

0

Unlock

11.14
-0.14 (-1.24%)
At close: Jan 24, 2025, 3:59 PM
11.18
0.36%
After-hours Jan 24, 2025, 04:00 PM EST

Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.

Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.

The company was incorporated in 2009 and is headquartered in San Diego, California.

Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc. Class A Common Stock logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Carmine N. Stengone MBA, MS

Contact Details

Address:
10578 Science Center Drive
San Diego, California
United States
Website https://www.contineum-tx.com

Stock Details

Ticker Symbol CTNM
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001855175
CUSIP Number n/a
ISIN Number US21217B1008
Employer ID 27-1467257
SIC Code 2834

Key Executives

Name Position
Carmine N. Stengone MBA, MS President, Chief Executive Officer, Secretary & Director
Peter T. Slover CPA Chief Financial Officer
Austin Chen Ph.D. Senior Vice President & Head of Research
Dr. Daniel S. Lorrain Ph.D. Chief Science Officer
Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D. Chief Medical Officer & Senior Vice President of Clinical Development
John Healy General Counsel & Corporate Secretary
Michael Mayberry Senior Director & Corporate Controller
Morgan Paulsen Senior Manager of Accounting
Steve E. Kunszabo Senior Director of Investor Relations & Corporate Communications

Latest SEC Filings

Date Type Title
Nov 27, 2024 4 Filing
Nov 20, 2024 4 Filing
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 06, 2024 10-Q Quarterly Report
Nov 06, 2024 8-K Current Report
Oct 31, 2024 SCHEDULE 13G Filing
Aug 14, 2024 4 Filing
Aug 14, 2024 10-Q Quarterly Report
Aug 14, 2024 8-K/A [Amend] Current Report
Aug 13, 2024 8-K Current Report